PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

Targeted biological therapies may achieve maximal therapeutic efficacy at doses below the maximum tolerated dose (MTD); therefore, the search for the MTD in clinical studies may not be ideal for these agents. Emactuzumab is an investigational monoclonal antibody that binds to and inhibits the activa...

Full description

Saved in:
Bibliographic Details
Published in:Clin Pharmacol Ther
Main Authors: Smart, Kevin, Bröske, Ann‐Marie, Rüttinger, Dominik, Mueller, Claudia, Phipps, Alex, Walz, Antje‐Christine, Ries, Carola, Baehner, Monika, Cannarile, Michael, Meneses‐Lorente, Georgina
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589268/
https://ncbi.nlm.nih.gov/pubmed/32575160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1964
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items